NDAORALTABLET, DELAYED RELEASE
Approved
Apr 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
VIMOVO (esomeprazole magnesium; naproxen) by Amgen is immediate-release esomeprazole magnesium layer and an enteric-coated naproxen core. Approved for adolescent patients 12 years of age, older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and 3 more indications. First approved in 2010.
Drug data last refreshed 9h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIMOVO is a fixed-dose combination oral tablet containing immediate-release esomeprazole magnesium (a proton pump inhibitor) and enteric-coated naproxen (an NSAID) designed to provide symptomatic relief of arthritis while reducing gastric ulcer risk. The dual-layer formulation releases esomeprazole first in the stomach to suppress acid production, then delivers naproxen in the small intestine to minimize gastrointestinal damage. This combination addresses a major safety concern in NSAID therapy by co-delivering gastroprotection with analgesia.
$0.003BPart D
LOE ApproachingDeclining
Product is in LOE-approaching phase with minimal Part D claims (1,223 in 2023), indicating a contracting franchise requiring strategic portfolio positioning and possible resource reallocation.
Mechanism of Action
immediate-release esomeprazole magnesium layer and an enteric-coated naproxen core. As a result, esomeprazole is released first in the stomach, prior to the dissolution of naproxen in the small intestine. The enteric coating prevents naproxen release at pH levels below 5.5. Naproxen is a NSAID with…
Indications (6)
Worked on VIMOVO at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.